Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 15, 2019

EC approves Roche’s MabThera for pemphigus vulgaris

Swiss pharma giant Roche has announced that the European Commission (EC) has approved its drug MabThera (rituximab) for rare autoimmune disease pemphigus vulgaris (PV).

By Allie Nawrat

Swiss pharma giant Roche has announced that the European Commission (EC) has approved its drug MabThera (rituximab) for rare autoimmune disease pemphigus vulgaris (PV).

This makes MabThera the first biologic to be approved in the European Union for this indication.

The recommendation was based upon a France-based Roche-sponsored Phase III trial named Ritux, which compared MabThera in combination with the current standard of care, corticosteroids, to the steroids alone.

The primary endpoint was remission at 24 months without the use of corticosteroids for at least two months. Results showed 89.5% of participants receiving MabThera achieved the endpoint, compared to 27.8% taking the corticosteroids.

Roche chief medical officer and head of global product development Sandra Horning said: “We’re pleased to bring the first biologic medicine to the more than 50,000 people in Europe suffering from pemphigus vulgaris.

“This MabThera approval provides a much needed new treatment that has been shown to provide higher remission rates than corticosteroids alone, which can cause debilitating side effects.”

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Roche is currently investigating MabThera’s efficacy and safety compared to immunosuppressant mycophenolate mofetil for PV.

PV involves progressive painful blistering of the skin and mucuous membranes, which can lead to life-threatening fluid loss, infection and death.

MabThera was approved for PV by the US Food and Drug Administration in June 2018. It is also approved in both Europe and the US for three blood cancers: relapsed follicular lymphoma, previously untreated diffuse large B-cell lymphoma and chronic lymphocytic leukaemia.

Combined with methotrexate MabThera is also indicated in the US for rheumatoid arthritis and combined with glucocorticoids is indicated for the treatment of adults with severe, active granulomatosis with polyangiitis and microscopic polyangiitis.

The drug is a monoclonal antibody that targets cells with a CD20 marker on their surface, which include normal B cells. It attacks these cells in collaboration with the body’s immune system.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy